Skip to Content

Scott E. Woodman, MD, PHD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7455 Fannin Street
Unit Number: 904
Houston, TX 77054
Room Number: 1SCR2.3022
Phone: 713-563-9286
Fax: 713-563-3424

Education & Training

Degree-Granting Education

2004 Albert Einstein College of Medicine, New York, NY, MD, Medical
2004 Albert Einstein College of Medicine, New York, NY, PHD, Molecular Pharmacology
2000 Albert Einstein College of Medicine, New York, NY, MS, Biomedical Science
1996 Michigan State University, East Lansing, MI, MA, Philosophy
1993 Hillsdale College, Hillsdale, MI, BS, Philosophy and Biology

Postgraduate Training

2007 Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
2004 Clinical Fellowship, Internal Medicine, Harvard Medical School, Boston, MA
2004 Clinical Residency, Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA

Board Certifications

2007 American Board of Internal Medicine

Experience/Service

Academic Appointments

Instructor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-6/2011

Honors and Awards

2010 Achievement in Basic Science Research Award, University of Texas MD Anderson Cancer Center
2010 Lupe C. Garcia Fellowship in Cancer Research, M. D. Anderson Cancer Center
2010 Travel Award, National Eye Institute, Association for Research in Vision and Opthamology
2009 Junior Investigator Award, Ocular Melanoma Foundation
2009 Merit Award, American Society for Clinical Oncology
2008 Carol Cogdell Courtney Fellowship, Melanoma Oncology, MD Anderson Cancer Center
2006-2007 Resident Teaching Award, Harvard Medical School Class of 2007
2005-2006 Outstanding Resident Teacher Award, Harvard Medical School, Shapiro Institute
2004 MD (Alpha Omega Alpha), Albert Einstein College of Medicine
2000 MS (Awarded with Distinction), Albert Einstein College of Medicine
1996-2004 Medical Scientist Training Program Grant, National Institutes Health
1996 MA (summa cum laude), Michigan State University
1993 BS (summa cum laude), Hillsdale College

Professional Memberships

Alpha Omega Alpha, Honor Medical Society
Member, 6/2004
American Society of Clinical Oncology
Member, 6/2009
Association for Research in Vision and Ophthalmology
Member, 6/2010

Selected Publications

Peer-Reviewed Original Research Articles
1. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer? Proc Natl Acad Sci U S A 107(48):20599-600, 11/2010. e-Pub 11/2010. PMCID: PMC2996413.
2. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568-74, 9/2010. e-Pub 5/2010. PMID: 20457136.
3. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.
4. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
5. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P, Medscape. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-40, 12/2008. e-Pub 10/21/2008. PMID: 18936790.

Last updated: 7/26/2011